VITA 34 AG

XETRA V3V.DE

VITA 34 AG Total Non-Current Liabilities for the year ending December 31, 2023: USD 87.64 M

VITA 34 AG Total Non-Current Liabilities is USD 87.64 M for the year ending December 31, 2023, a 22.02% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

VITA 34 AG Total Non-Current Liabilities for the year ending December 31, 2022 was USD 71.83 M, a -13.13% change year over year.
VITA 34 AG Total Non-Current Liabilities for the year ending December 31, 2021 was USD 82.68 M, a 222.05% change year over year.
VITA 34 AG Total Non-Current Liabilities for the year ending December 31, 2020 was USD 25.67 M, a 2.06% change year over year.
VITA 34 AG Total Non-Current Liabilities for the year ending December 31, 2019 was USD 25.15 M, a 0.50% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

XETRA: V3V.DE

VITA 34 AG

CEO	Mr. Jakub Julian Baran
IPO Date	March 27, 2007
Location	Germany
Headquarters	Deutscher Platz 5a
Employees	745
Sector	Healthcare
Industries Biotechnology 3D Printing Plastics

Description

VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous immune cells; and CAR-T. In addition, the company manufactures advanced therapy medicinal products based on mesenchymal stem cells for experimental treatment by specialized medical institutions; preserves stem cells from perinatal tissue and adult body fat; and engages in the contract manufacturing of pharmaceutical intermediates. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.

Key trends

Past 5 years